ISSN Print 2713-2757
ISSN Online 2713-2765
SCIENTIFIC AND PRACTICAL REVIEWED JOURNAL OF FMBA OF RUSSIA
ORIGINAL RESEARCH
Dynamics of humoral immunity to SARS-CoV-2 in the professionally homogeneous group of people over a two-year period of COVID-19 outbreak
About authors
State Research Institute of Biological Instrumentation of the Federal Medical Biological Agency, Moscow, Russia
Correspondence should be addressed: Vera G. Pomelova
Volokolamskoe shosse, 75, corp. 1, Moscow, 125424, Russia; ur.neercsonummi@avolemop.v
About paper
Acknowledgements: we would like to thank staff members of the State Research Institute of Biological Instrumentation: Kanaeva TA for carrying out immunochipbased analysis, Balaban AS for antigen printing with nanoplotter and immunochip preparation for analysis, Stadnik OB for management of the serum samples acquisition and testing using commercially available immunoassay kit.
Author contribution: Pomelova VG — concept, experimental design, manuscript writing; Bychenkova TA — management of immunochip-based immunochemistry studies, data processing; Bekman NI — statistical analysis, preparation of illustrations; Osin NS — providing technical assistance, data analysis and discussion, manuscript editing; Ishkov YuN, Styazhkin KK — data analysis and discussion, manuscript editing.
Compliance with ethical standards: the study was approved by the Ethics Committee of the State Research Institute of Biological Instrumentation (protocol № 4 dated June 09, 2021). The informed consent was submitted by all subjects.
Received: 2022-05-19
Accepted: 2022-06-04
Published online: 2022-06-16
|
Fig. 1. Monthly distribution of people getting COVID-19 (histograms) and vaccinated with Sputnik V (curve) over the two-year observation period
Fig. 2. А. Distribution of the serum levels of antibodies against SARS-CoV-2 in COVID-19 survivors. 0 — before the disease onset (n = 16); I — 2–8 (n = 14); II — 9–16 (n = 17); III — 17–24 (n = 14); IV — 25–36 (n = 22); V — 37–68 (n = 15). B. Distribution of the serum levels of antibodies against SARS-CoV-2 in people vaccinated with Sputnik V. 0 — before vaccination (n = 38); I — 6–8 (n = 10); II — 9–16 (n = 24); III — 17–24 (n = 12); IV — 25–36 (n = 12). Median values with 95% CI are provided for А and B (red dot). C. Median IgG levels for the observation period. 0 — before the disease onset or vaccination; I — 2–8 (survivors) or 6–8 (vaccinated individuals); II — 9–16; III — 17–24; IV — 25–36; V — 37–68. Median IgG levels are provided for the disease survivors (red line) and vaccinated people (blue dotted line)
Fig. 3. Distribution of the serum levels of antibodies against SARS-CoV-2 in groups H (n = 70), D (n = 84), D + V (n = 32), V (n = 58), and V + RV (n = 14). Median values with 95% CI are provided (red dot)
Table 1. General characteristics of blood sera donors
Note: * — extreme points of the age range (16, 76, 78, 88 years) are represented by relatives of the research institute staff members; ** — including 3 people revaccinated with Sputnik Light about 6 months after receiving the first dose of Sputnik V; * * * — booster vaccination with Sputnik V, 2 doses (8 people), Sputnik Light (4 people) or CoviVac, 2 doses (2 people) 6–9 months after receiving the first dose of Sputnik V.
Table 2. Serum anti-SARS-CoV-2 IgG levels as a function of gender and age
Note: CI — Confidence Interval; * — the difference between the groups is statistically significant.
Table 3. Characteristics of new COVID-19 cases in staff members having a history of the disease and vaccinated individuals
Note: * — IgG level on day 42 after administration of the first vaccine dose; ** — IgG level on day 90 after administration of the first vaccine dose; * * * — IgG level at the time of the disease onset.
